- Recommendation ID
- NG161/1
- Question
Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received systemic anticancer treatment (SACT) (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?
- Any explanatory notes
(if applicable) It is recommended that this research should also consider:
- if there are specific types of SACT carrying increased risk of poor outcomes from COVID-19
- if there are specific types of cancer for which SACT may carry increased risk of poor outcomes from COVID-19
- if there is a difference in any risk of poor outcomes from COVID-19 between people who have received SACT alone, radiotherapy alone, or both SACT and radiotherapy
- if there is a difference in any risk of poor outcomes from COVID-19 between children and young people who have received SACT and adults who have received SACT
Source guidance details
- Comes from guidance
- COVID-19 rapid guideline: delivery of systemic anticancer treatments
- Number
- NG161
- Date issued
- March 2020
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 30/09/2021 |